Enveric Biosciences, Inc. (ENVB) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Enveric Biosciences, Inc. is a biotechnology company developing small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders. The company's lead candidate, EB-003, is in preclinical development targeting depression and anxiety. The company operates as a single segment and is classified as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,633,473) | $(2,184,966) |
| Operating Expenses | $1,633,170 | $2,187,533 |
| Cash and Cash Equivalents (End of Period) | $4,908,769 | $4,294,435 |
| Working Capital | $4,914,423 | N/A |
| Net Cash Used in Operating Activities | $(2,256,839) | $(2,391,582) |
| Net Cash Provided by Financing Activities | $2,503,208 | $4,448,914 |
| Accumulated Deficit | $(116,479,965) | $(108,259,471) |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by approximately 25% to $1.63 million from $2.19 million in Q1 2025. This was driven by a 54% decrease in Research and Development (R&D) expenses (from $746k to $346k) and an 8% decrease in General and Administrative (G&A) expenses.
- Capital Raising: The company raised approximately $2.5 million in net proceeds during Q1 2026 through a Registered Direct Offering ($1.2 million net) and an At-The-Market (ATM) agreement ($1.3 million net). This contrasts with Q1 2025, which saw over $4.4 million in financing proceeds.
- Share Structure: A 1-for-12 reverse stock split was effected in October 2025. All share data in this filing is retroactively adjusted. As of March 31, 2026, 1,887,535 shares of common stock were outstanding.
Outlook, Risks, and Management Commentary
- Going Concern Warning: The filing explicitly states that the company's current cash on hand is insufficient to satisfy operating needs for the 12 months following the filing date. This raises substantial doubt about the company's ability to continue as a going concern.
- Subsequent Financing: In April 2026 (post-period), the company raised approximately $4.5 million in net proceeds via a private placement and received $1.5 million from warrant exercises. Management plans to raise additional capital through equity or debt financings to sustain operations.
- Development Pipeline: The primary focus remains on advancing EB-003 toward an Investigational New Drug (IND) filing. The company also unveiled the EVM401 Series to broaden its pipeline for addiction and neuropsychiatric disorders.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2026, due to material weaknesses identified in the prior year related to limited personnel, segregation of duties, and documentation.
Investor Verification Checklist
- Verify the sufficiency of the $4.5 million raised in April 2026 to cover the burn rate of ~$2.25 million per quarter.
- Confirm the timeline and regulatory status of the IND filing for lead candidate EB-003.
- Review the remediation plan for material weaknesses in internal controls over financial reporting.
- Monitor the dilution impact from the significant number of outstanding warrants (1.64 million shares) and options.
- Assess the status of the out-licensed EVM201 Series program with MycoMedica for potential milestone payments.